Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Neil S. Forbes
University of Massachusetts Amherst, Department: Engineering (All Types)
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ernest Pharmaceuticals, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The outside financial interest has a nexus of conflict with the investigator's research activities because it arises from and relies upon the academic expertise that qualifies the investigator to participate in the NIH funded research; in addition, Ernest Pharmaceuticals is seeking to option and/or license previously disclosed intellectual property invented by Professor Forbes and Ms. Nele Van Dessel funded by NIH under a previous grant and that is being furthered via the current research funded by NIH under award #5R01CA188382-03. While the start-up entity has thus far been largely nascent (minimal activity, minimal value), Professor Forbes anticipates it will seek to option a license to intellectual property on which he is a named inventor.
Targeting epigenetic regulators using bacterial macromolecule delivery
The experimental plan describes a therapeutic strategy to target epigenetic tumor regulators by using bacteria to controllably deliver genes and proteins into cancer cells. In this project, bacteria will be engineered to deliver shRNA, targeting NIPP1 and EZH2, and NIPP1-based peptides that dissociate NIPP1:PP1 complexes. This research will establish a new therapeutic platform that will enable targeting of cancer genes for which no therapy currently exists.
Filed on August 14, 2017.
Tell us what you know about Neil S. Forbes's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.